Kinetics of myeloid-derived suppressor cell frequency and function during simian immunodeficiency virus infection, combination antiretroviral therapy, and treatment interruption

Journal of Immunology

Volumn 198, Issue 2, 2017, Pages 757-766

  Dross, Sandra E ^a,b   Munson, Paul V ^a   Kim, Se Eun ^b   Bratt, Debra L ^a   Tunggal, Hillary C ^a   Gervassi, Ana L ^b   Fuller, Deborah H ^a   Horton, Helen ^a,c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b SEATTLE BIOMEDICAL RESEARCH INSTITUTE   (United States)

^c JANSSEN RESEARCH FOUNDATION   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CYTOKINE; EMTRICITABINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE MIGRATION INHIBITION FACTOR; RALTEGRAVIR; TENOFOVIR DISOPROXIL; TUMOR NECROSIS FACTOR;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIRETROVIRAL THERAPY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL COUNT; CELL FUNCTION; CELL KINETICS; CELL PROLIFERATION; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG WITHDRAWAL; IMMUNE DEFICIENCY; IMMUNE RESPONSE; LENTIVIRUS INFECTION; LONGITUDINAL STUDY; MALE; MYELOID-DERIVED SUPPRESSOR CELL; NONHUMAN; POLYCLONAL ACTIVATION; PROTEIN EXPRESSION; RHESUS MONKEY; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; TREATMENT INTERRUPTION; VIREMIA; VIRUS LOAD; ANIMAL; DRUG EFFECTS; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FLOW CYTOMETRY; IMMUNOLOGY; SIMIAN IMMUNODEFICIENCY VIRUS; VIROLOGY;

ANIMALS; ANTI-RETROVIRAL AGENTS; ENZYME-LINKED IMMUNOSORBENT ASSAY; ENZYME-LINKED IMMUNOSPOT ASSAY; FLOW CYTOMETRY; MACACA MULATTA; MYELOID-DERIVED SUPPRESSOR CELLS; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 85014698748     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1600759     Document Type: Article

References (35)

1. Gabrilovich, D. I., and S. Nagaraj. 2009. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9: 162-174
2. Talmadge, J. E., and D. I. Gabrilovich. 2013. History of myeloid-derived suppressor cells. Nat. Rev. Cancer 13: 739-752
3. Diaz-Montero, C. M., M. L. Salem, M. I. Nishimura, E. Garrett-Mayer, D. J. Cole, and A. J. Montero. 2009. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol. Immunother. 58: 49-59
4. Weed, D. T., J. L. Vella, I. M. Reis, A. C. De la Fuente, C. Gomez, Z. Sargi, R. Nazarian, J. Califano, I. Borrello, and P. Serafini. 2015. Tadalafil reduces myeloid-derived suppressor cells and regulatory T cells and promotes tumor immunity in patients with head and neck squamous cell carcinoma. Clin. Cancer Res. 21: 39-48
5. Kusmartsev, S., F. Cheng, B. Yu, Y. Nefedova, E. Sotomayor, R. Lush, and D. Gabrilovich. 2003. All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Res. 63: 4441-4449
6. Nagaraj, S., J. I. Youn, H. Weber, C. Iclozan, L. Lu, M. J. Cotter, C. Meyer, C. R. Becerra, M. Fishman, S. Antonia, et al. 2010. Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer. Clin. Cancer Res. 16: 1812-1823
7. Mishalian, I., Z. Granot, and Z. G. Fridlender. 2017. The diversity of circulating neutrophils in cancer. Immunobiology 222: 82-88
8. Scapini, P., and M. A. Cassatella. 2014. Social networking of human neutrophils within the immune system. Blood 124: 710-719
9. Gervassi, A., N. Lejarcegui, S. Dross, A. Jacobson, G. Itaya, E. Kidzeru, S. Gantt, H. Jaspan, and H. Horton. 2014. Myeloid derived suppressor cells are present at high frequency in neonates and suppress in vitro T cell responses. PLoS One 9: e107816
10. Schmitz, J. E., M. J. Kuroda, S. Santra, V. G. Sasseville, M. A. Simon, M. A. Lifton, P. Racz, K. Tenner-Racz, M. Dalesandro, B. J. Scallon, et al. 1999. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 283: 857-860
11. Elahi, S., W. L. Dinges, N. Lejarcegui, K. J. Laing, A. C. Collier, D. M. Koelle, M. J. McElrath, and H. Horton. 2011. Protective HIV-specific CD8+ T cells evade Treg cell suppression. Nat. Med. 17: 989-995
12. Ndhlovu, Z. M., L. B. Chibnik, J. Proudfoot, S. Vine, A. McMullen, K. Cesa, F. Porichis, R. B. Jones, D. M. Alvino, M. G. Hart, et al. 2013. High-dimensional immunomonitoring models of HIV-1-specific CD8 T-cell responses accurately identify subjects achieving spontaneous viral control. Blood 121: 801-811
13. Brenchley, J. M., D. A. Price, T. W. Schacker, T. E. Asher, G. Silvestri, S. Rao, Z. Kazzaz, E. Bornstein, O. Lambotte, D. Altmann, et al. 2006. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat. Med. 12: 1365-1371
14. Younas, M., C. Psomas, J. Reynes, and P. Corbeau. 2016. Immune activation in the course of HIV-1 infection: causes, phenotypes and persistence under therapy. HIV Med. 17: 89-105
15. Giorgi, J. V., L. E. Hultin, J. A. McKeating, T. D. Johnson, B. Owens, L. P. Jacobson, R. Shih, J. Lewis, D. J. Wiley, J. P. Phair, et al. 1999. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J. Infect. Dis. 179: 859-870
16. Vollbrecht, T., R. Stirner, A. Tufman, J. Roider, R. M. Huber, J. R. Bogner, A. Lechner, C. Bourquin, and R. Draenert. 2012. Chronic progressive HIV-1 infection is associated with elevated levels of myeloid-derived suppressor cells. AIDS 26: F31-F37
17. Bowers, N. L., E. S. Helton, R. P. Huijbregts, P. A. Goepfert, S. L. Heath, and Z. Hel. 2014. Immune suppression by neutrophils in HIV-1 infection: role of PDL1/PD-1 pathway. PLoS Pathog. 10: e1003993
18. Qin, A., W. Cai, T. Pan, K. Wu, Q. Yang, N. Wang, Y. Liu, D. Yan, F. Hu, P. Guo, et al. 2013. Expansion of monocytic myeloid-derived suppressor cells dampens T cell function in HIV-1-seropositive individuals. J. Virol. 87: 1477-1490
19. Gama, L., E. N. Shirk, J. N. Russell, K. I. Carvalho, M. Li, S. E. Queen, J. Kalil, M. C. Zink, J. E. Clements, and E. G. Kallas. 2012. Expansion of a subset of CD14highCD16negCCR2low/neg monocytes functionally similar to myeloidderived suppressor cells during SIVand HIV infection. J. Leukoc. Biol. 91: 803-816
20. Sui, Y., A. Hogg, Y. Wang, B. Frey, H. Yu, Z. Xia, D. Venzon, K. McKinnon, J. Smedley, M. Gathuka, et al. 2014. Vaccine-induced myeloid cell population dampens protective immunity to SIV. J. Clin. Invest. 124: 2538-2549
21. Fuller, D. H., P. A. Rajakumar, M. S. Wu, C. W. McMahon, T. Shipley, J. T. Fuller, A. Bazmi, A. M. Trichel, T. M. Allen, B. Mothe, et al. 2006. DNA immunization in combination with effective antiretroviral drug therapy controls viral rebound and prevents simian AIDS after treatment is discontinued. Virology 348: 200-215
22. Garg, A., and S. A. Spector. 2014. HIV type 1 gp120-induced expansion of myeloid derived suppressor cells is dependent on interleukin 6 and suppresses immunity. J. Infect. Dis. 209: 441-451
23. Sandler, N. G., H. Wand, A. Roque, M. Law, M. C. Nason, D. E. Nixon, C. Pedersen, K. Ruxrungtham, S. R. Lewin, S. Emery, et al; INSIGHT SMART Study Group. 2011. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J. Infect. Dis. 203: 780-790
24. Grützner, E., R. Stirner, L. Arenz, A. P. Athanasoulia, K. Schrödl, C. Berking, J. R. Bogner, and R. Draenert. 2016. Kinetics of human myeloid-derived suppressor cells after blood draw. J. Transl. Med. 14: 2
25. Kotsakis, A., M. Harasymczuk, B. Schilling, V. Georgoulias, A. Argiris, and T. L. Whiteside. 2012. Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samples. J. Immunol. Methods 381: 14-22
26. Trellakis, S., K. Bruderek, J. Hütte, M. Elian, T. K. Hoffmann, S. Lang, and S. Brandau. 2013. Granulocytic myeloid-derived suppressor cells are cryosensitive and their frequency does not correlate with serum concentrations of colonystimulating factors in head and neck cancer. Innate Immun. 19: 328-336
27. Kumar, V., S. Patel, E. Tcyganov, and D. I. Gabrilovich. 2016. The nature of myeloid-derived suppressor cells in the tumor microenvironment. Trends Immunol. 37: 208-220
28. Gabrilovich, D. I., S. Ostrand-Rosenberg, and V. Bronte. 2012. Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 12: 253-268
29. Wu, L., H. Du, Y. Li, P. Qu, and C. Yan. 2011. Signal transducer and activator of transcription 3 (Stat3C) promotes myeloid-derived suppressor cell expansion and immune suppression during lung tumorigenesis. Am. J. Pathol. 179: 2131-2141
30. Simpson, K. D., D. J. Templeton, and J. V. Cross. 2012. Macrophage migration inhibitory factor promotes tumor growth and metastasis by inducing myeloidderived suppressor cells in the tumor microenvironment. J. Immunol. 189: 5533-5540
31. Santos-Oliveira, J. R., E. G. Regis, C. B. Giacoia-Gripp, J. G. Valverde, P. Alexandrino-de-Oliveira, J. A. Lindoso, H. Goto, M. P. Oliveira-Neto, J. O. Guerra, B. Grinsztejn, et al. 2013. Microbial translocation induces an intense proinflammatory response in patients with visceral leishmaniasis and HIV type 1 coinfection. J. Infect. Dis. 208: 57-66
32. Calandra, T., and T. Roger. 2003. Macrophage migration inhibitory factor: a regulator of innate immunity. Nat. Rev. Immunol. 3: 791-800
33. Delaloye, J., I. J. De Bruin, K. E. Darling, M. K. Reymond, F. C. Sweep, T. Roger, T. Calandra, and M. Cavassini. 2012. Increased macrophage migration inhibitory factor (MIF) plasma levels in acute HIV-1 infection. Cytokine 60: 338-340
34. Zhao, X., L. Rong, X. Zhao, X. Li, X. Liu, J. Deng, H. Wu, X. Xu, U. Erben, P. Wu, et al. 2012. TNF signaling drives myeloid-derived suppressor cell accumulation. J. Clin. Invest. 122: 4094-4104
35. Nazli, A., O. Chan, W. N. Dobson-Belaire, M. Ouellet, M. J. Tremblay, S. D. Gray-Owen, A. L. Arsenault, and C. Kaushic. 2010. Exposure to HIV-1 directly impairs mucosal epithelial barrier integrity allowing microbial translocation. PLoS Pathog. 6: e1000852.